Clinical pharmacological test of calcium alginate capsules -Optimization study of postprandial serum triglyceride elevation suppression effect (additional preliminary study)
- Conditions
- Healthy subjects
- Registration Number
- JPRN-UMIN000052532
- Lead Sponsor
- Takasaki University of Health and Welfare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Not provided
Persons receiving treatment, medication, or lifestyle guidance from a doctor due to dyslipidemia or diabetes. People who regularly use medicines, health foods, or supplements that affect blood lipids. Persons who have some kind of disease and are receiving medication and are deemed unsuitable as subjects by the research doctor. Persons who may have allergic symptoms related to rubber or latex. Persons who may develop allergic symptoms regarding fat-loaded foods (corn oil, etc.). Persons whose HIV antigen/antibody, HBs antigen, HCV antibody, or syphilis test result was positive at the time of screening. Persons with obvious abnormalities found in hematological or biochemical tests. Those who are pregnant, wish to become pregnant during the test, or are breastfeeding. Persons whose TG delta C3h (estimated TGCmax) is less than 30 mg/dL in the screening test. Those who have been diagnosed with bronchial asthma and are receiving treatment, or those who have received treatment in the past.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The area under the curve (AUC) of the postprandial serum triglyceride.
- Secondary Outcome Measures
Name Time Method The maximum concentration (Cmax) of the postprandial serum triglyceride. The serum triglyceride level (before, 60, 90, 120, 240 and 360 minutes after the fat food load).